CVRx (CVRX) Stock Analysis & AI Equity Report
CVRx (CVRX) overview
CVRx (CVRX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 56.7m and operating profit of USD -51.3m; the year-end share price was 7.10 USD and market capitalisation was USD 187m. CVRx is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get CVRx's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About CVRx
CVRx develops, manufactures and commercializes neuromodulation medical devices for cardiovascular disease. Its Barostim implant delivers electrical pulses to baroreceptors in the carotid artery, providing Baroreflex Activation Therapy for patients with heart failure. The therapy is designed to affect signaling between the cardiovascular system and the autonomic nervous system and is used alongside guideline-directed medical therapy. Barostim is approved in the United States for heart failure.
Generate the CVRx report
CVRx is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for CVRx and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on CVRx
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.